SAN FRANCISCO, Nov. 22, 2016 /PRNewswire/ -- Symic Bio, a clinical stage biopharmaceutical company focused on extracellular matrix biology developing a new category of therapeutics, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline and progress at the upcoming Piper Jaffray Healthcare Conference.
Conference details are as follows:
Date: Tuesday, November 29, 2016
Time: 7:30 a.m. EST
Location: Lotte New York Palace, New York
About Symic Bio
Symic Bio is a clinical stage biopharmaceutical company focused on extracellular matrix biology that is developing a new category of therapeutics. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules of the extracellular matrix. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061 directed at disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.
For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
Investor Contacts
Lisa Burns or Bill Slattery, Jr. Burns McClellan, Inc.(212) 213-0006 [email protected]
Media Contacts
David Schull or Rich AllanRusso Partners, LLC(212) 845-4271(646) [email protected] [email protected]
Advertisement
Conference details are as follows:
Date: Tuesday, November 29, 2016
Time: 7:30 a.m. EST
Advertisement
Location: Lotte New York Palace, New York
About Symic Bio
Symic Bio is a clinical stage biopharmaceutical company focused on extracellular matrix biology that is developing a new category of therapeutics. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules of the extracellular matrix. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061 directed at disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.
For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
Investor Contacts
Lisa Burns or Bill Slattery, Jr. Burns McClellan, Inc.(212) 213-0006 [email protected]
Media Contacts
David Schull or Rich AllanRusso Partners, LLC(212) 845-4271(646) [email protected] [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symic-bio-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-300367247.html
SOURCE Symic Bio
